SKIN 
 

January 2023     Volume 7 Issue 1 
 

(c) 2022 THE AUTHORS. Published by the National Society for Cutaneous Medicine. 629 

BRIEF ARTICLE 
 

 

Unilateral and Localized Bullous Eruption in a 71-year-old 
Woman 
 

Karishma Daftary, BA1, Raj Chovatiya, MD, PhD1 

 
1Department of Dermatology, Feinberg School of Medicine at Northwestern University, Chicago, IL 
 

 
 

 
 
A 71-year-old South Asian woman presented 
with a 2-month, pruritic, bullous eruption 
localized only to the right leg, refractory to 
topical triamcinolone. Her history was notable 
for a stage IVB small-cell neuroendocrine 
tumor in the mediastinum diagnosed two 
years prior. Following initial carboplatin and 
etoposide, she was transitioned to combined 
ipilimumab / nivolumab for the past year. Her 
tumor treatment course was notable for 
autoimmune hypothyroidism secondary to 
immunotherapy. She had otherwise stable 
disease without progression. Skin 
examination revealed tense bullae filled with 
clear fluid, denuded vesicles, and post-
inflammatory hyperpigmentation at sites of 
healed bullae localized only to the right mid-
lateral leg (Figure 1). 
 
Punch biopsy of an active bulla revealed a 
subepidermal acantholysis with spongiosis 
and numerous eosinophils, and direct 
immunofluorescence showed linear IgG and 
C3 deposits at the dermal-epidermal junction 
(Figure 2). These findings were consistent 
with unilateral, localized bullous pemphigoid 
(LBP). The eruption resolved completely 
without recurrence following twice-daily 
betamethasone dipropionate 0.05% 
ointment. 

 
 
Bullous pemphigoid (BP) is the most 
commonly occurring autoimmune blistering 
dermatosis, affecting predominantly elderly 
patients in the 7th decade of life. It classically 
presents with diffuse pruritus and bullae. 
Pathogenesis involves autoantibodies 
directed at hemidesmosomal proteins 
located at the dermal-epidermal junction – 
most commonly BP230 and BP180 (BP 
antigens 1 and 2, respectively). Because 
these proteins are expressed throughout the 
skin, BP typically presents in a diffuse, 
symmetric pattern. In addition to thorough 
physical examination, diagnosis of BP is 
made with histology demonstrating 
subepidermal blisters with eosinophils, 
immunofluorescence depicting linear 
deposits of IgG and C3 along the basement 
membrane, and quantification of 
autoantibodies using enzyme-linked 
immunoassay. 
 
LBP is a variant of BP in which lesions are 
restricted to certain sites. This variant is 
uncommon, with a recent cohort study 
suggesting a prevalence of 2.5% among BP 
patients.1 LBP often arises in areas of 
previous trauma or radiation and has been 
more frequently reported in the pretibial, 
vulvar, peristomal, and umbilical regions.2  

CASE REPORT DISCUSSION 



SKIN 
 

January 2023     Volume 7 Issue 1 
 

(c) 2022 THE AUTHORS. Published by the National Society for Cutaneous Medicine. 630 

 
Figure 1. Bullae localized to the right mid-lateral leg. 

 
Figure 2. (A) Lesional punch biopsy of active bulla 
demonstrating subepidermal acantholysis with 
spongiosis and numerous eosinophils (hematoxylin & 
eosin, 10X); Peri-lesional punch biopsy showing IgG 
(B) and C3 (C) deposits at the dermal-epidermal 
junction (direct immunofluorescence, 10X).

The disease course is more benign than 
generalized BP due to its responsiveness to 
topical steroids, though LBP may also 
progress to generalized disease.3,4 
 
Triggering factors implicated in the 
development of LBP include radiation, burns, 
surgical procedures, phototherapy, venous 
stasis, and bacterial infections.1 Several 
medications (e.g., angiotensin-converting-
enzyme inhibitors, loop diuretics, gabapentin, 
iodine, dithranol, and tar) have also been 
reported to cause this variant.5 In our case, 
immunotherapy was the likely causative 
factor leading to the development of LBP. 
While widespread immunobullous eruptions 
like BP are well-described cutaneous 
adverse reactions associated with anti-

CTLA-4 and -programmed cell death protein-
1 (PD-1) immunotherapy, reports of LBP 
following the use of these medications are 
extraordinarily rare.6  
 
Diagnosis of LBP is often delayed compared 
to generalized BP, as the differential 
diagnosis of a localized bullous eruption on 
the leg is broad and includes trauma (e.g., 
burn, friction, pressure), edema, arthropod 
assault, contact dermatitis, leukocytoclastic 
vasculitis, bullous diabeticorum, acute 
eczema, photodermatitis, and infection 
(namely herpesvirus and bacterial). For new-
onset bullous eruptions in patients receiving 
immunotherapy, it is important to consider 
clinical correlation alongside skin biopsy and 



SKIN 
 

January 2023     Volume 7 Issue 1 
 

(c) 2022 THE AUTHORS. Published by the National Society for Cutaneous Medicine. 631 

immunofluorescence to differentiate between 
etiologies. 
 
Conflict of Interest Disclosures: RC has served as 
an advisory board member, consultant, and/or 
investigator for AbbVie, Arcutis, Arena, Argenx, 
Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly 
and Company, EPI Health, Incyte, LEO Pharma, 
L’Oréal, National Eczema Association, Pfizer Inc., 
Regeneron, Sanofi, and UCB, and speaker for 
AbbVie, Arcutis, Dermavant, Eli Lilly and Company, 
EPI Health, Incyte, LEO Pharma, Pfizer Inc., 
Regeneron, Sanofi, and UCB. KD has no conflicts to 
disclose. 
 
Funding: None 
 
Corresponding Author: 
Raj Chovatiya, MD, PhD 
Department of Dermatology 
Northwestern University Feinberg School of Medicine 
676 N St Clair St, Suite 1600 
Chicago, IL 60611 
Email: raj.chovatiya@gmail.com

 
 
References: 
1. Ständer S, Kasperkiewicz M, Thaçi D, et al. 

Prevalence and presumptive triggers of 
localized bullous pemphigoid. J Dermatol 
2021;48(8):1257-1261. (In eng). DOI: 
10.1111/1346-8138.15912. 

2. Bernard P, Antonicelli F. Bullous 
Pemphigoid: A Review of its Diagnosis, 
Associations and Treatment. Am J Clin 
Dermatol 2017;18(4):513-528. (In eng). DOI: 
10.1007/s40257-017-0264-2. 

3. Salomon RJ, Briggaman RA, Wernikoff SY, 
Kayne AL. Localized bullous pemphigoid. A 
mimic of acute contact dermatitis. Arch 
Dermatol 1987;123(3):389-92. (In eng). DOI: 
10.1001/archderm.123.3.389. 

4. Wang Y, Mao X, Liu Y, Li L. Localized 
bullous pemphigoid: a case report. Ann 
Transl Med 2020;8(5):249. (In eng). DOI: 
10.21037/atm.2020.01.104. 

5. Wenzel D, Droms R, St John J, Luffman C, 
Levin NA. Localized bullous pemphigoid after 
knee replacement surgery. Dermatol Online J 
2021;27(3) (In eng). 

6. Amber KT, Valdebran M, Lu Y, De Feraudy 
S, Linden KG. Localized pretibial bullous 
pemphigoid arising in a patient on 
pembrolizumab for metastatic melanoma. J 

Dtsch Dermatol Ges 2018;16(2):196-198. (In 
eng). DOI: 10.1111/ddg.13411.